SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-23-172591
Filing Date
2023-06-22
Accepted
2023-06-22 16:32:29
Documents
1
Group Members
FRANK M. SANDSSANDS CAPITAL GLOBAL VENTURE FUND II, L.P.SANDS CAPITAL LIFE SCIENCES PULSE FUND, LLCSANDS CAPITAL PRIVATE GROWTH FUND III-DC, L.P.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d499106dsc13da.htm SC 13D/A 105767
  Complete submission text file 0001193125-23-172591.txt   107805
Mailing Address 400 EAST JAMIE COURT SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 400 EAST JAMIE COURT SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-566-1402
DICE Therapeutics, Inc. (Subject) CIK: 0001645569 (see all company filings)

IRS No.: 472286244 | State of Incorp.: DE | Fiscal Year End: 1230
Type: SC 13D/A | Act: 34 | File No.: 005-92879 | Film No.: 231033778
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O SANDS CAPITAL VENTURES, LLC 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209
Business Address C/O SANDS CAPITAL VENTURES, LLC 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209 703-562-4000
Sands Capital Life Sciences Pulse Fund II, L.P. (Filed by) CIK: 0001875620 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9
Type: SC 13D/A